Accepted for Publication: December 21, 2021.
Published Online: March 10, 2022. doi:10.1001/jamaoncol.2022.0001
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Giuliano AR et al. JAMA Oncology.
Corresponding Author: Anna R. Giuliano, PhD, Moffitt Cancer Center, MRC-CANCONT, 12902 Magnolia Dr, Tampa, FL 33612 (firstname.lastname@example.org).
Author Contributions: Dr Giuliano had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Giuliano, Lancet, Pilon-Thomas, Dong, Tan, Tworoger, Siegel, Mo, Cubitt, Dukes.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Giuliano, Lancet, Pilon-Thomas, Tan, Ball, Cubitt, Dukes, Hensel.
Critical revision of the manuscript for important intellectual content: Giuliano, Lancet, Pilon-Thomas, Dong, Jain, Tworoger, Siegel, Whiting, Mo, Cubitt, Dukes, Hensel, Keenan, Hwu.
Statistical analysis: Dong, Whiting, Mo.
Obtained funding: Giuliano, Tworoger.
Administrative, technical, or material support: Pilon-Thomas, Dong, Jain, Tan, Tworoger, Cubitt, Dukes, Hensel, Keenan, Hwu.
Supervision: Giuliano, Pilon-Thomas, Ball, Cubitt.
Conflict of Interest Disclosures: Dr Giuliano reported receiving grants from Merck & Co, Inc, through Moffitt Cancer Center and personal fees from Merck & Co, Inc, as an advisory board member outside the submitted work. Dr Lancet reported receiving personal fees from Novartis, Bristol Myers Squibb, AbbVie, Astellas Pharma, Takeda Pharmaceutical Co, Daiichi Sankyo, Jazz Pharmaceuticals, Agios Pharmaceuticals, ElevateBio, and Jasper Therapeutics, Inc, outside the submitted work. Dr Tworoger reported receiving grants from the US Department of Defense, Florida Department of Health, and the National Institutes of Health outside the submitted work. Dr Hwu reported receiving grants from Merck & Co, Inc, and from the National Cancer Institute–designated comprehensive cancer center funded in part by a Moffitt Cancer Center support grant during the conduct of the study; he reported receiving personal fees from the Dragonfly Scientific Advisory Board and Immatics Scientific Advisory Board outside the submitted work. No other disclosures were reported.
Funding/Support: This work was funded in part by the Moffitt Cancer Center’s support grant P30CA076292, which supported the center’s Total Cancer Care staff; Chemical Biology Core; the Participant Research, Interventions, and Measurement Core; Cancer Pharmacokinetics and Pharmacodynamics Core; Tissue Core; and Biostatistics and Bioinformatics Shared Resource Core. The state of Florida funds provided to the Moffitt Center for Immunization and Infection Research in Cancer also supported this study. This work was additionally supported in part by research grant MISP 60276 from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp. Development of SARS-CoV-2 reagents was partially supported by the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance contract HHSN272201400008C.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the staff of the Krammer Laboratory at the Icahn School of Medicine at Mount Sinai for providing receptor binding domain and spike expression vectors. We also thank Ligia Pinto, PhD, Frederick National Laboratory for Cancer Research, for the methods to measure IgG responses against the receptor binding domain and S proteins of SARS-CoV-2. They did not receive compensation beyond their usual salary for their contribution to this study.
P , Khaki
AR , Wise-Draper
et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol
. 2021;32(6):787-800. doi:10.1016/j.annonc.2021.02.024
D , Amanat
F , Chromikova
et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr Protoc Microbiol
. 2020;57(1):e100. doi:10.1002/cpmc.100
AR , Pilon-Thomas
S , Schell
et al. SARS-CoV-2 period seroprevalence and related factors: Hillsborough County, Florida, October 2020-March 2021. Emerg Infect Dis
. 2022;28(3). Published online January 26, 2022. doi:10.3201/eid2803.211495PubMedGoogle ScholarCrossref
ME , Blake
M , Chilleo
C , Wells
A , Haidar
G . Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era. Open Forum Infect Dis
. 2021;8(7):ofab353. doi:10.1093/ofid/ofab353
N , Suthar
MS , Makowski
et al; mRNA-1273 Study Group. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med
. 2021;384(23):2259-2261. doi:10.1056/NEJMc2103916
LJ , Chemaitelly
H , Butt
AA ; National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med
. 2021;385(2):187-189. doi:10.1056/NEJMc2104974